KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt repayments
Ratios

Labcorp Holdings (LH) EBIAT (2016 - 2026)

Labcorp Holdings' EBIAT history spans 18 years, with the latest figure at $277.8 million for Q1 2026.

  • On a quarterly basis, EBIAT rose 30.42% to $277.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $941.7 million, a 28.58% increase, with the full-year FY2025 number at $877.7 million, up 17.48% from a year prior.
  • EBIAT hit $277.8 million in Q1 2026 for Labcorp Holdings, up from $164.9 million in the prior quarter.
  • Over the last five years, EBIAT for LH hit a ceiling of $491.6 million in Q1 2022 and a floor of -$199.5 million in Q4 2022.
  • Historically, EBIAT has averaged $191.1 million across 5 years, with a median of $212.9 million in 2023.
  • Biggest five-year swings in EBIAT: crashed 153.67% in 2022 and later soared 186.63% in 2024.
  • Tracing LH's EBIAT over 5 years: stood at -$199.5 million in 2022, then rose by 16.39% to -$166.8 million in 2023, then soared by 186.63% to $144.5 million in 2024, then grew by 14.12% to $164.9 million in 2025, then soared by 68.47% to $277.8 million in 2026.
  • Business Quant data shows EBIAT for LH at $277.8 million in Q1 2026, $164.9 million in Q4 2025, and $261.1 million in Q3 2025.